Truist raised the firm’s price target on CVS Health (CVS) to $98 from $95 and keeps a Buy rating on the shares. The firm remains bullish on CVS post an upbeat Investor Day highlighting the company’s differentiated collection of assets, strong positioning and opportunities across segments, alongside the announced launch of a centralized engagement platform in FY26, the analyst tells investors in a research note. Brisk cash flow and ongoing balance sheet improvement underpins continued core growth investment, the firm added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Health price target raised to $95 from $88 at Mizuho
- CVS Health price target raised to $92 from $82 at Baird
- CVS Health price target raised to $93 from $89 at Morgan Stanley
- CVS Health price target raised to $101 from $99 at Piper Sandler
- CVS Health price target raised to $93 from $87 at Barclays